Australian based biosimilar manufacturer NeuClone has started phase 1 trials of its version of ustekinumab and has plans to launch other biosimilars for gastroenterology-related conditions. The Sydney-based manufacturer says it has commenced a dosing trial in Australian centres of a ustekinumab biosimilar candidate, NeuLara, in over 200 healthy volunteers. If approved by the TGA, the ...
Australian company has biosimilars in the pipeline for Crohn’s and colitis
7 Nov 2019